Vor Bio jumps after late-stage data for immune disorder drug

Shares of drug developer Vor Bio VOR.O rise ~37% to $2.26 premarket

Co and Chinese partner RemeGen's 688331.SS experimental drug met the main goal of a late-stage study in China for the treatment of Sjögren's disease

VOR says the drug, telitacicept, significantly reduced disease severity in patients with the autoimmune condition that damages the glands that produce and control moisture in the body

Telitacicept showed a favorable safety profile in the study - VOR

VOR signed a licensing deal in June to develop and commercialize telitacicept outside China

Telitacicept is being tested to treat another immune disorder, generalized myasthenia gravis, in a global late-stage study

Up to last close, stock was up 49.5% YTD